Human CD20 is a B-cell lineage-specific marker expressed by normal and leukemic B cells from the preB to the plasma-cell stages and is a target for rituximab (RTX) immunotherapy. A CD20 reverse-transcriptase-polymerase chain reaction on B-cell lines cDNA yielded a short PCR product (ΔCD20) corresponding to a spliced mRNA transcript linking the exon3 and exon7 ends. We established here that this novel, alternatively spliced CD20 transcript is expressed and detectable at various levels in leukemic, lymphoma, in vivo tonsil-or in vitro CD40L-activated B cells, in EBV-transformed B cells, but not in resting CD19+-or CD20+-sorted B cells from peripheral blood or bone marrow of healthy donors. The truncated CD20 sequence is within the reading frame, codes a protein of 130 amino acids (~15-17 kD) lacking large parts of the four transmembrane segments, suggesting that ΔCD20 is a non-anchored membrane protein. We demonstrated the translation into a ΔCD20 protein which is associated with the membrane CD20 protein and showed its involvement in RTX resistance. Study of patient's samples before and after RTX-resistance or -escape confirms our in vitro findings.
Introduction

CD20 (MS4A1) is a 33-to 37-kD non-glycosylated transmembrane (TM) phosphoprotein
that is widely expressed throughout B-lymphocyte ontogeny, in normal or malignant B-cells.
1
The 16-kb gene encoding human CD20, consisting of 8 exons, has been mapped to chromosome 11 (11q12-q13) and belongs to the MS4A (membrane spanning 4A) gene family localized within a cluster of related genes (MS4A1 to MS4A11).
2 Its transcription leads to three mRNA isoforms: a dominant 2.8-kb transcript, using exons 1 to 8 a second exon 1-spliced transcript shorter by 263 bp; and a third, minor 3.4-kb transcript, 3 all encoding a fulllength CD20 protein.
The CD20 protein consists of cytoplasmic N-and C-termini and four hydrophobic regions for anchoring the molecule in the membrane. 4 Three isoforms have been identified, including a predominant 33-kD molecule and two isoforms of 34.5 and 36 kD, resulting from differential phosphorylation states (on serine and threonine residues) in relation to B-cell stimulation and proliferation. 5 CD20 appears to play a role in Ca ++ conductance 6 and is also involved in cell cycle progression by interaction with src family kinases. 7 Finally, a circulating form has been identified in chronic lymphocytic leukemia (CLL), Hodgkin's disease, or non-Hodgkin lymphoma (NHL), and in healthy individuals.
8
CD20 expression at the cell surface of malignant B cells makes it a target for monoclonal antibody (MAb) therapy. Rituximab (RTX), the first FDA-approved MAb for clinical therapy, targets the CD20 antigen 9 and leads to CD20-expressing B-cell depletion through different mechanisms 9-10 [for review, see Cartron et al 11 ] . Thus, RTX is widely used against B-cell malignancies and also for autoimmune diseases such as rheumatoid arthritis, 12 steroid refractory chronic graft-versus-host disease (GvHD), 13 or posttransplant lymphoproliferative disease, 14 and for treatment of refractory kidney transplant humoral rejection. Retroviral CD20 gene transfer was proposed as an alternative suicide gene therapy to improve the system of genetically modified T-lymphocyte adoptive transfers. [24] [25] [26] Because transcriptional regulation through aberrant alternative splicing is an emerging mechanism involved in cancer progression 27 and was previously associated with resistance to transgenic T-cell depletion, 28 we analyzed CD20 transcriptional regulation in CD20-transduced cells.
We indentified a novel CD20 alternative mRNA (ΔCD20), demonstrating that this splice variant mRNA encodes a truncated protein and providing evidence that ΔCD20 is directly correlated with RTX resistance. Moreover, ΔCD20 splice mRNA was absent from normal B cells isolated from healthy donors and present in malignant B cells, making it a molecular marker of choice for diagnosis or molecular minimal residual disease follow-up.
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From PCR) was performed from 2 μl of cDNA using primers specific from the start (exon 3) and the stop codon (exon 8), respectively: Fw-hCD20-start (5-ATGACAACACCCAGAAATTC-3') and R-hCD20-stop (5'-TTAAGGAGAGCTGTCATTTTCT-3').
For specific and more sensitive amplification (ΔCD20-PCR) of the identified splice variant, a primer Fw-ΔhCD20 (5'-GATGTCTTCACTGG/AACT-3') spanning the junction was used in combination with the R-hCD20-stop primer. PCR was performed using BIOTAQ polymerase (Bioline, Abscys, France) in standard conditions. Annealing temperature was 58°C for both fl-and ΔCD20-PCR.
For CD20 mRNA transcript expression analysis, real-time PCR (RT-qCPR) was performed using pairs of primers to specifically amplify the full-length form of CD20, as follows: TQMFw-hCD20-wt (5'-GAGCCAATGAAAGGCCCTATT-3') and TQM-R-hCD20-wt (5'-AAGAAGCTTTGCGTGGGGCC-3'; complementary of the spliced region). For specific analysis of the spliced forms of mRNA CD20, a reverse primer TQM-R-ΔhCD20 (5'-AGCTATTACAAGTT/CCAGTG-3') spanning the junction was used in combination with the TQM-Fw-hCD20-wt. PCR products were revealed using a dual-labeled Fam/Tamra Taqman probe: TQM-probe-hCD20 (5'-ATGCAATCTGGTCCAAAACCACTCTTCAGG-3'). To determine the sequence of the CD20 variant and of the site-directed mutated form (mutCD20), we performed cycle sequencing on a 3130 DNA analyzer, directly from PCR-or gel-purified products, in both directions using the Cycle Sequencing Kit v3.1 (Applied Biosystems, Courtaboeuf, France).
Computational analysis: splice-site prediction and site-directed mutagenesis
We performed computer-assisted analysis for splice-site and branched-point prediction using NetGene2 (release 2.4) (http://www.cbs.dtu.dk/services/NetGene2) and NNsplice v0.9
(http://www.fruitfly.org/seq_tools/splice.html). We designed site-directed mutagenesis For personal use only. on November 12, 2017. by guest www.bloodjournal.org From primers for acceptor site (AS) mutation using the online program QuikChange® Primer Design Program (http://www.stratagene.com/sdmdesigner/default.aspx) from Stratagene.
Generation of plasmids and retroviral constructs, site-directed mutagenesis, and production of packaging cell lines flCD20 and ΔCD20 forms were cloned into a pcDNA 3.1/CT-GFP (green fluorescent protein) vector (Invitrogen, Paisley, UK) for expressing a CD20/GFP fusion protein to study subcellular protein localization.
The degeneracy of the genetic code allowed a change of the third nucleotide of the AS codon at position 612, from CAG (Gln) to CAA (Gln). Primers used were G612A-Fw 5'-GATCTTTGCCTTCTTCCAAGAACTTGTAATAGCTGGC-3' and G612A-R 5'-GCCAGCTATTACAAGTTCTTGGAAGAAGGCAAAGATC-3'.
Finally, both these and the site-directed-mutated form of the CD20 (mutCD20) were cloned into the retroviral pLXSN vector (Clontech, Saint-Germain-en-Laye, France).
Supernatant was produced from PG13 amphotropic packaging cell line.
Establishment of RTX resistance, immunophenotyping, and in vitro complementdependent cytolysis (CDC) assay
Establishment of RTX resistance was performed as previously described. 31 Briefly, Ramos and Raji B-cell lines (group N), adjusted to 1.10 6 cells/ml, were serially (four times) exposed for 24 h to a low dose of RTX (0.5 μg/ml) to generate the R1 group, or three times in the presence of escalating high doses of RTX (2 and 64 μg/ml) for generating the R2 group. RTX exposure was done in presence of 25% of newborn rabbit serum (NRS) or 50% Human serum (HS) as a source of complement. Ficoll gradient centrifugation was applied after each RTX Experiments were performed 15 days after the last RTX exposure.
Confocal microscopy, slide preparation, and immunofluorescence staining and western blotting Cells were spread onto poly-L-lysine-coated slides (Sigma, France), fixed with paraformaldehyde 4%, and washed. After blocking with 20% fetal bovine serum and washing, cells were stained with the appropriate mAbs or directly visualized using GFP LASER excitation. Stacks of confocal images were collected with an FV1000-laser-scanning confocal microscope (Olympus, France). Cell nuclei were counterstained with DAPI (4',6-diamidino-2-phenylindole).
For the western blotting study, cells were lysed with sample buffer (2% SDS in 125-mM Tris-Hcl, pH=6.8). Cytoplasm and membrane subcellular fractions were harvested after differential ultracentrifugation in adapted buffers; the presence or absence of subcellular specific proteins by western blot attested to subcellular separation. Proteins were extracted 
Results
From alternative splicing, a novel isoform of human CD20 (ΔCD20) mRNA arises, devoid of the sequence coding for the four major TM domains From the reverse transcription and PCR of full-length CD20 (flCD20) cDNA, synthesized from Raji or Daudi B-cell lines, using two primers respectively complementary of the start and stop codon regions, we observed a PCR product smaller (393 bp) than the expected size (894 bp) (Figure 1 ). Sequencing analysis showed that the smaller transcript (ΔCD20) was identical to the wild-type (wt) MS4A1 sequence published in NCBI Genbank (NM_021950.3) but lacked an internal 501-bp fragment, corresponding to part of exon 3 to part of exon 7.
Therefore, the open reading frame remained conserved. This ΔCD20 splice form transcript differs from previously described 2.8-and 3.4-kb alternative dominant MS4A1 forms 3 and from other known transcripts of the MS4A gene family. Furthermore, smaller PCR products we obtained from all of the screened B-cell lines were similar in length. In silico sequence analysis of the full-length CD20 sequence, using the NetGene2 and NNsplice v0.9 programs, showed putative donor ("GT," localized in exon 3) and acceptor ("AG," localized exon 7)
sites, as well as a branched site, ("A," nt 594 of the coding sequence), corresponding exactly to the open reading frame of the smaller transcript ΔCD20. This deletion covered nucleotides 111 to 612 (from the +1 ATG nucleotide) and removed codons 37 to 204. Thus, this new inframe cDNA encodes a putative novel isoform of CD20 ( Figure S1 , supplemental material) , and T-CLL (n=2) and T-ALL (n=1) cell lines. In addition to the flCD20 transcript PCR products (894 bp), we detected ΔCD20 transcripts of PCR products (393 bp) in all screened malignant and EBV-transformed B-cell lines but not T-cell lines ( Figure 2A ). To confirm these results, we designed a PCR assay (ΔCD20-PCR) allowing specific and more sensitive detection of the spliced transcripts, using a forward primer spanning the splice junction. The expected 295-bp PCR product was detected in all previously screened B-cell lines. We confirmed specificity of the ΔCD20 RTPCR assay by absence of amplification from T-cell-line-derived cDNA and from a plasmid vector carrying the flCD20.
As a control, each short PCR product was sequenced, enabling confirmation that each 393-bp amplicon corresponded to ΔCD20 (data not shown).
To determine if this specific CD20 alternatively spliced form is expressed only in transformed B cells, we searched for the ΔCD20 isoform in cDNA synthesized from PBMCs (n=7) and bone marrow mononuclear cells (BMMCs) (n=5) derived from healthy donors using both flCD20-and ΔCD20-RTPCR. Moreover, we screened immunomagnetically CD20+-purified B cells, and because ΔCD20 may modulate CD20 cell surface membrane expression, we also studied CD19+-purified B cells. We detected no alternative transcripts, even with the ΔCD20 PCR assay, either in BMMC or in CD20+-and CD19+-PBMC purified B cells ( Figure 2B ). In addition, we investigated ΔCD20 expression in B-EBV-transformed cell lines (n=4) ( Figure 2B ), in in-vitro activated B lymphocytes, and in CD19+ from tonsillectomy samples. All expressed the ΔCD20-spliced form. A kinetic study on B-EBV or CD40L-activated B blasts revealed the truncated form of ΔCD20 all over the culture when For personal use only. on November 12, 2017. by guest www.bloodjournal.org From stimuli were maintained. However, for B blasts, the signal decreased 72 h after initial CD40L activation (data not shown).
Translation of in-frame ΔCD20 alternative transcript codes for a protein
In silico translation analysis show that splicing of the CD20 gene results in in-frame transcript coding for a ΔCD20 protein. Splicing affected a cysteine amino acid, implying an effect in a disulfide bond in a major part of the TM domain (five amino acids of the TM4 domain remain) but not the phosphorylation sites. To explore this issue and to confirm the existence of the ΔCD20 protein, we used transfected 293T cells with a vector carrying wt and Δ-CD20 cDNA fused with the GFP sequence, allowing expression of wt and Δ-CD20/GFP fusion proteins, respectively, examined under confocal microscopy. We thus detected protein expression with either anti-CD20 Ab staining or after GFP excitation. As expected, while GFP signal was detected for both constructs, the anti-CD20 antibody, recognizing the deleted region, emitted fluorescence only for the full-length protein. The anti-CD20 antibody, specific to the C-terminus (C-term) region, recognized both complete and truncated ΔCD20 proteins ( Figure 3A ).
Using western blot analysis with the C-term region anti-CD20 Ab, we detected, in addition to the expected size length (35-37 kD) of the wtCD20, an additional signal at 15-17 kD in all screened B-cell lines (Figure 3B, left) . This size length correlated with the putative coded protein translated from the ΔCD20 alternative transcript described above. Signal was detected only in B-cell lines (n=4) but not in T-cell lines (n=3).We also detected the same signal in five native samples from CLL-(Supplemental figure S2 ) and MCL-patient samples. More precisely, the 15-17-kD signal split into two distinct bands, as generally detected for the wtCD20 protein; these bands correspond to different phosphorylation states, as previously described, 23 in which the smaller band is the unphosphorylated form. Remarkably, band intensity corresponding to the ΔCD20 protein phosphorylation status differed between cell lines, as illustrated in Figure 3B ; the lower band was more intense for JY, the upper band was more intense for SkW 6-4 and Daudi, and the intensity remained similar in the ROS cell line.
For confirmation that the 15-17-kD protein correlated with ΔCD20 transcript translation,
we transduced a Raji cell line with a retroviral vector carrying the ΔCD20 cDNA sequence and obtained a significant 2.96-fold increase in signal at position 15-17 kD, indicating again that the ΔCD20 mRNA encodes a protein ( Figure 3B , right). Interestingly, the signal intensity of the wtCD20 band decreased (fold change, 0.68). Altogether, these results demonstrated that ΔCD20 alternative mRNA is translated into protein.
Finally, to demonstrate that the smaller product is not a breakdown product, we analyzed PI-positive (death) versus PI-negative (live) cells after RTX exposure. As reported in supplemental figure S3 , presence of ΔCD20mRNA and protein was detected on both cell fractions.
ΔCD20 alternative transcripts are the source of the ΔCD20 protein with an abnormal intracellular compartmentalization
To confirm that the splice signals (donor site, DS, and AS) are the source of the ΔCD20 mRNA and protein, we modified the nucleotide sequence to delete one of these sites, the AS site, codon 612, from CAG (Gln) to CAA (Gln). FACS analysis indicated that this new mutated protein is expressed and addressed at the membrane ( Figure 4A ). RT-PCR analysis, with fl-or ΔCD20-PCR assays, confirmed that a packaging cell line transfected with retroviral vector carrying the mutated CD20 (mutCD20) did not generate splice ΔCD20 mRNA ( Figure 4B ). Confocal analysis of mutCD20/GFP fusion-transfected 293T cells revealed that the mut-CD20 protein was expressed and recognized by both anti-CD20
antibodies ( Figure 3A ). We did not detect a signal at the expected 15-17-kD size length using
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From different packaging of PG13 clones and western blot analysis with the c-term anti-CD20 antibody that recognizes the ΔCD20 protein, confirming the absence of translation of splice ΔCD20 protein. We did, however, still detect the truncated protein within wtCD20-transfected PG13 clones ( Figure 4C ). Overall, the mutagenesis results with the splice AS sequence confirmed that the splice signal is the source of the ΔCD20 mRNA and protein.
In silico translation of the in-frame ΔCD20 mRNA indicated that much of the four TM domains of the CD20 protein is deleted (5 amino acids remaining), signifying that the ΔCD20 may be a non-anchored protein. To address this issue, we performed western blot analysis of different subcellular fractions of cytoplasm and membrane. As shown Figure 4D for four Bcell lines, the ΔCD20 signal occurred in the membrane subfraction but not in the cytoplasm.
Moreover, immunoprecipitation with an anti-wtCD20 antibody revealed by western blot that the ΔCD20 protein co-immunoprecipitated, suggesting an association between ΔCD20 and wtCD20 protein (Supplemental Figure S4 ).
The alternatively spliced ΔCD20 form is associated with resistance to RTX treatment
While CD20 is the target of one of the most-used immunotherapy drugs in hematology, it is important to assess if the newly discovered ΔCD20 protein is involved in the response to treatment. To answer this question, we induced RTX resistance in Raji and Ramos B-cell lines by serial exposure to escalating doses of RTX (0.5 to 64 μg/ml). Resistance acquisition was confirmed by in vitro CDC lysis assay and assessment of cell surface staining of CD20 by FACS analysis. Cell lysis in the presence of RTX + complement was 96%, 60%, and 52%, respectively, for native Ramos, R2 -2, and R2 -64, whereas it was close to 10% in the absence of complement. CDC assay showed also that the RTX resistance is established at least for 21 days post last RTX exposure (Supplemental Table 1 ).
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From Western blot analysis using the anti-C-term CD20 region antibody, revealed increased signal at 15-17 kD, corresponding to the ΔCD20 protein ( Figure 5B ) in relation to RTX exposure and independently of the complement source, human or newborn serum. This finding was confirmed, in addition to burkitt (RAMOS or RAJI), also in pre-B (ROS) cell lines (Supplemental figure S5 ) and also by quantitative analysis of the signal in which the protein ratio of ΔCD20/wtCD20 signals similarly increased ( Figure 5C , left and supplemental Figure S5 ). Quantitative experiments at the mRNA level, using RT-qPCR assay, showed that the level of ΔCD20 mRNA transcripts increased with RTX exposure, in line with the western blot experiments ( Figure 5C , right). Moreover, the protein ratio of ΔCD20:wt CD20 as well as % of ΔCD20 mRNA correlated with RTX (5 μg/ml) sensitivity (respectively R 2 =0.9234 and R 2 =0.9688). Finally, ΔCD20 mRNA quantification was stable in different phase of the cell cycle (Supplemental figure S6 ). This important result might suggest that the portion of the B cells expressing ΔCD20 protein escaped RTX elimination.
ΔCD20 mRNA is found in activated B-cells and in human different B-cell Malignancies
To quantify the spliced form of CD20 in different B malignancies, we designed an RTqPCR assay allowing specific quantification of both flCD20 and ΔCD20 transcripts, assessed using respective reverse primers complementary to the deleted area or spanning the splicing junction ( Figure 6A ). A cross-amplification experiment was performed from Daudi cDNA and plasmids carrying each form of transcript. flCD20-qPCR detected PCR product from Daudi (Ct=18) and flCD20-plasmid (Ct=12.7) but not from ΔCD20 plasmid, while ΔCD20
qPCR gave an amplification signal from Daudi (Ct=34) and ΔCD20-plasmid (Ct=11.8) but not from flCD20-plasmid. These results confirmed the specificity of both assays and showed that the ΔCD20 form is less abundant that the flCD20 (Ct wt =18 vs Ct Δ =34 in Daudi). Both (supplemental figure S7) . Interestingly, screening of a panel of B-cell hematologic malignancies in PB or BM showed that the spliced form is detectable at various levels. We found a mean of 3.6±5.1% in B-ALL (n=27); 3.9±5.3% in FL (n=5); 2.9±4.5% in MCL (n=6); 3.2±2.2% in DLBCL (n=5); and 0.1±0.2% in B-CLL (n=8). In diagnosis tumors samples (Lymphe nodes, spleen or pleural) quantification of the splice form of CD20mRNA is (Mean ± ES) showed, compare to BM or PB, a similar level as 2.8±1.7% in FL (n=3), 3 ±2.3% in MCL (n=5), 1.3±2.3% in MZL (n=5), 0.81±0.8% in CLL (n=5)] while a higher level as 13.9±5.9% in DHBCL (n=3). (Figure 6B ). Finally, RT-qPCR confirmed qualitative screening in which the spliced form was not detected in PBMCs (n=5) or BMMCs (n=5) from healthy donors as well as in CD138+ plasmocytes from multiple myeloma (n= 16) ( Figure   6B ).
In addition, we quantified ΔCD20 mRNA on pre (sensitive) and post (resistant) RTX primary cells from patients carrying FL (n=3) or MCL (n=3). We observed an increase of ΔCD20 mRNA in all cases of RTX escape (Fold change of x1.14 to x23.64, median 3.38) except for the case of FL that didn't initially respond to RTX treatment and where the ΔCD20 mRNA level on post-RTX sample biopsy remain similar or slightly lower to the pre-RTX sample (FC=x0.71) ( Figure 6C ). 
Discussion
We describe here a new splice CD20 variant (ΔCD20) that differs from two previously reported variants and also from those identified in two genome-wide analyses describing different MS4A variants and their putative translated proteins. 2, 33 This novel ΔCD20 mRNA is expressed in-frame from the ATG start codon within exon 3 and fuses part of exon 3 to exon 7, leading to a coded protein lacking the extracellular domain (including the RTX epitope sequence
32
) and much of the four TM-spanning domains.
We also provide here, for the first time, substantial evidence that this spliced ΔCD20 mRNA variant is naturally translated into a protein. Confocal microscopy and western blot results on B-cell lines, using a C-term CD20 antibody, showed that in-frame mRNA ΔCD20
transcript codes for a putative protein of 15-17 kD. Second, the 15-17-kD signal band was consequently increased after transduction of the Raji cell line with a retroviral vector carrying the ΔCD20 cDNA sequence. We also demonstrated, with site-directed mutagenesis of the AS that results in an absence of splicing, that the CD20-spliced mRNA is the source of this new ΔCD20 protein. Interestingly, this mutated/corrected CD20 cDNA sequence may also be an interesting tool for gene suicide therapy using gene-modified T cells to modulate alloreactivity post-BM graft. 25 To our knowledge, these results are the first demonstration that the ΔCD20 exists.
As shown after Raji cell transduction by a retroviral vector carrying the ΔCD20 cDNA, while ΔCD20 protein expression increased, wtCD20 protein expression decreased, suggesting a relation between the two. Moreover, western blot on subcellular fractions showed that the ΔCD20 protein is harvested within the membrane compartment. In addition, anti-CD20
immunoprecipitation with an anti-CD20 antibody recognizing only the wtCD20 protein indicated an association of both proteins, ΔCD20/wtCD20, rather than an anchor by the remnant of the TM domains (five amino acids).
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From A careful review of previous studies identifies reports of lower additional bands through western blot using an anti-CD20 antibody, but none of these studies addressed these additional smaller molecular species as the product of the translation of a potential alternative ΔCD20 transcript. Czuczman et al 20 assigned this additional lower band to the light chains of IgM, while Kennedy et al, 34 in the case of a CLL patient treated with RTX, concluded that this lower band may have corresponded to a partial digestion product of the CD20 protein.
20
Although CD20 is the cell surface target of the best-known immunotherapy (RTX) for treating B-cell malignancies or various autoimmune diseases, its function remains unclear.
RTX is administered, with or without chemotherapy, for various CD20-positive B-cell lymphoproliferative disorders. In spite of the known efficiency of RTX, some NHL patients exhibit poor or no clinical response to RTX monotherapy, 35 and repeated exposure leads to relapse/resistance to RTX therapy.
Many factors influence RTX response at the protein level. 16, [19] [20] 23, 31 One interesting and important finding in the current work is that RTX resistance leads to increased ΔCD20 signal, suggesting that some CD20-expressing B cells persist despite RTX treatment. Many examples of gene-expression modulation by an associated mRNA variant have been reported in B cells. [36] [37] As shown here, after western blot on the ΔCD20-transduced Raji cell line, ΔCD20
protein seemed to modulate wtCD20 expression, thus leading to reduced wtCD20 expression as evaluated on patient samples in DLBCL and correlated with inferior survival. 38 The ΔCD20 protein may also interact with the wtCD20 protein and modulate CD20 reorganization within the lipid raft and contribute to the development of RTX resistance. Moreover, detection by western blotting of two forms of the ΔCD20 protein may correspond to different states of phosphorylation, as previously described for the wtCD20 protein; 
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